المؤلفون: Yuankai Shi, Kaijian Lei, Yuming Jia, Bingqiang Ni, Zhiyong He, Minghong Bi, Xicheng Wang, Jianhua Shi, Ming Zhou, Qian Sun, Guolei Wang, Dongji Chen, Yongqian Shu, Lianke Liu, Zhongliang Guo, Yong Liu, Junquan Yang, Ke Wang, Ke Xiao, Lin Wu, Tienan Yi, Debin Sun, Mafei Kang, Tianjiang Ma, Yimin Mao, Jinsheng Shi, Tiegang Tang, Yan Wang, Puyuan Xing, Dongqing Lv, Wangjun Liao, Zhiguo Luo, Bin Wang, Xiaohong Wu, Xiaoli Zhu, Shuhua Han, Qisen Guo, Rongyu Liu, Zhiwei Lu, Jianyong Zhang, Jian Fang, Changlu Hu, Yinghua Ji, Guolong Liu, Hong Lu, Dedong Wu, Junhong Zhang, Shuyang Zhu, Zheng Liu, Wensheng Qiu, Feng Ye, Yan Yu, Yanqiu Zhao, Qinhong Zheng, Jun Chen, Zhanyu Pan, Yiping Zhang, Wenjuan Lian, Bo Jiang, Bo Qiu, Guojun Zhang, Hua Zhang, Yanju Chen, Yuan Chen, Hongbing Duan, Manxiang Li, Shengming Liu, Lijun Ma, Hongming Pan, Xia Yuan, Xueli Yuan, Yulong Zheng, Emei Gao, Li Zhao, Shumin Wang, Can Wu

المصدر: Cancer Communications, Vol 41, Iss 9, Pp 889-903 (2021)

مصطلحات موضوعية: anti‐angiogenesis, anti‐VEGF monoclonal antibody, avastin, bevacizumab, biosimilar, non‐small cell lung cancer, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2523-3548Test

الوصول الحر: https://doaj.org/article/1b6a8c7c86df46eb82dde4f6b77d922eTest

المؤلفون: Zhongliang Guo, Jian Fang, Junhong Zhang, Puyuan Xing, Xiaoli Zhu, Changlu Hu, Yuming Jia, Ming Zhou, Zhiwei Lu, Bin Wang, Ke Wang, Yiping Zhang, Lin Wu, Zhanyu Pan, Yanju Chen, Junquan Yang, Shuhua Han, Yongqian Shu, Lianke Liu, Bingqiang Ni, Yong Liu, Hongming Pan, Rongyu Liu, Shengming Liu, Qian Sun, Feng Ye, Qinhong Zheng, Guojun Zhang, Tiegang Tang, Tianjiang Ma, Jianyong Zhang, Bo Jiang, Mafei Kang, Zhiguo Luo, Wenjuan Lian, Can Wu, Lijun Ma, Zhiyong He, Wensheng Qiu, Dongqing Lv, Zheng Liu, Qisen Guo, Dedong Wu, Ke Xiao, Xia Yuan, Jun Chen, Yan Yu, Yuankai Shi, Guolei Wang, Dongji Chen, Shuyang Zhu, Jianhua Shi, Guolong Liu, Hua Zhang, Hongbing Duan, Bo Qiu, Wangjun Liao, Shumin Wang, Jinsheng Shi, Tienan Yi, Hong Lu, Xueli Yuan, Emei Gao, Yimin Mao, Xicheng Wang, Li Zhao, Xiaohong Wu, Yanqiu Zhao, Yan Wang, Kaijian Lei, Yinghua Ji, Yulong Zheng, Minghong Bi, Manxiang Li, Debin Sun, Yuan Chen

المصدر: Cancer Communications, Vol 41, Iss 9, Pp 889-903 (2021)
Cancer Communications

مصطلحات موضوعية: 0301 basic medicine, Oncology, non‐small cell lung cancer, Cancer Research, medicine.medical_specialty, China, anti‐angiogenesis, Lung Neoplasms, Bevacizumab, LY01008, bevacizumab, law.invention, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Humans, Stage (cooking), Biosimilar Pharmaceuticals, avastin, RC254-282, vascular endothelial growth factor, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Original Articles, Carboplatin, 030104 developmental biology, Treatment Outcome, chemistry, Paclitaxel, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Toxicity, anti‐VEGF monoclonal antibody, Original Article, biosimilar, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3df18b6bb21c6add27ccbf366193128eTest
https://doaj.org/article/1b6a8c7c86df46eb82dde4f6b77d922eTest